Mineral adjuvants

Immunopotentiators in Modern Vaccines

Volumn , Issue , 2006, Pages 217-233

  Lindblad, Erik ^a  

^a Brenntag Biosector   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33846822293     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088403-2/50014-9     Document Type: Chapter

References (100)

1. Aggerbeck H., Fenger C., Heron I. Booster vaccination against diphtheria and tetanus in man. Comparison of calcium phosphate and aluminium hydroxide as adjuvants: II. Vaccine 1995, 13:1366-1374.
2. Al-Shakhshir R.H., Regnier F.E., White J.L., Hem S.L. Contribution of electrostatic and hydrophobic interactions to the adsorption of proteins by aluminium-containing adjuvants. Vaccine 1995, 13:41-44.
3. Aprile M.A., Wardlaw A.C. Aluminium compounds as adjuvants for vaccines and toxoids in man: a review. Can. J. Public Health 1966, 57:343-354.
4. Asea A., Kraeft S-K., Kurt-Jones E.A., Stevenson M.A., Chen L.B., Finberg R.W., Koo G.C., Calderwood S.K. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and a cytokine. Nature Med. 2000, 6:435-442.
5. Asea A., Rehli M., Kabingu E., Boch J.A., Bare O., Auron P.E., Stevenson M.A., Calderwood S.K. Novel signal transduction pathway utilized by extracellular HSP70. J. Biol. Chem. 2002, 277:15028-15034.
6. Authier F.J., Cherin P., Creange A., Bonnotte B., Ferrer X., Abdelmoumni A., Ranoux D., Pelletier J., Figarella-Branger D., Granel B., Maisonobe T., Coquet M., Degos J.D., Gherardi R.K. Central nervous system disease in patients with macrophagic myofasciitis. Brain 2001, 124(Pt 5):974-983.
7. Bergfors E., Trollfors B., Inerot A. Unexpectedly high incidence of persistent itching nodules and delayed hypersensitivity to aluminium in children after use of adsorbed vaccines from a single manufacturer. Vaccine 2003, 22:64-69.
8. Böhler-Sommeregger K., Lindemayr H. Contact sensitivity to aluminium. Contact Dermatitis 1986, 15:278-281.
9. Bomford R. The comparative selectivity of adjuvants for humoral and cell-mediated immunity: II. Effect on delayed-type hypersensitivity in the mouse and guinea pig, and cell-mediated immunity to tumour antigens in the mouse of Freund's incomplete and complete adjuvants, Alhydrogel, Corynebacterium parvum, Bordetella pertusis, muramyl dipeptide and saponin. Clin. Exp. Immunol. 1980, 39:435-441.
10. Brewer J.M., Conacher M., Satoskar A., Bluethmann H., Alexander J. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Eur. J. Immunol. 1996, 26:2062-2066.
11. Butler N.R., Voyce M.A., Burland W.L., Hilton M.L. Advantages of aluminium hydroxide adsorbed combined diphtheria, tetanus, and pertussis vaccines for the immunization of infants. Brit. Med. J. 1969, 1:663-666.
12. Carlow C.K.S., Bianco A.E. Resistance of Onchocerca lienalis microfilariae in mice conferred by egg antigens of homologous and heterologous onchocerca species. Parasitology 1987, 94:485-496.
13. Chaby R., Caroff M. Lipopolysaccharides of Bordetella pertussis endotoxin. Pathogenesis and Immunity in Pertussis 1988, 247-271. John Wiley, New York. A.C. Wardlaw, P. Parton (Eds.).
14. Code of Federal Regulations 2003.
15. Collier L.H., Polakoff S., Mortimer J. Reactions and antibody responses to reinforcing doses of adsorbed and plain tetanus vaccines. Lancet 1979, 1364-1367.
16. Coursaget P., Yvonnet B., Relyveld E.H., Barres J.L., Diop-Mar I., Chiron J.P. Simultaneous administration of diphtheria-tetanus-pertussis-polio and hepatitis B vaccines in a simplified immunization program: immune response to diphtheria toxoid, tetanus toxoid, pertussis, and hepatitis B surface antigen. Infect. Immun. 1986, 51:784-787.
17. Cvjetanovic B., Uemura K. The present status of field and laboratory studies of typhoid and paratyphoid vaccines. Bull. WHO 1965, 32:29-36.
18. Dagoussat N., Robillard V., Haeuw J.F., Plotnicky-Gilquin H., Power U., Corvaia N., Nguyen T., Bonnefoy J.Y., Beck A. A novel bipolar mode of attachment to aluminium-containing adjuvants by BBG2Na, a recombinant subunit hRSV vaccine. Vaccine 2001, 19:4143-4152.
19. 4 on purified influenza virus hemagglutinins in man. J. Immunol. 1968, 100:1139-1140.
20. Dillon S.B., Demuth S.G., Schneider M.A., Weston C.B., Jones C.S., Young J.F., Scott M., Bhatnaghar P.K., LoCastro S., Hanna N. Induction of protective class I MHC-restricted CTL in mice by a recombinant influenza vaccine in aluminium hydroxide adjuvant. Vaccine 1992, 10:309-318.
21. Edelman R. Vaccine adjuvants. Rev. Infect. Dis. 1980, 2:370-383.
22. Ericsson H. Purification and adsorption of diphtheria toxoid. Nature 1946, 158:350-351.
23. European Pharmacopoeia Vaccines for human use 1997, 1697. 3rd edn.
24. 26Al. Vaccine 1997, 15:1314-1318.
25. Flebbe L.M., Braley-Mullen H. Immunopotentiating effects of the adjuvants SGP and Quil-A: I. Antibody responses to T-dependent and T-independent antigens. Cell. Immunol. 1986, 99:119-127.
26. Francis M.J., Fry C.M., Rowlands D.J., Brown F., Bittle J.L., Houghten R.A., Lerner R.A. Immunological priming with synthetic peptides of foot-and-mouth disease virus. J. Gen. Virol. 1985, 66:2347-2354.
27. Francis M.J., Fry C.M., Rowlands D.J., Bittle J.L., Houghten R.A., Lerner R.A., Brown F. Immune response to uncoupled peptides of foot-and-mouth disease virus. Immunology 1987, 61:1-6.
28. Frost L., Johansen P., Pedersen S., Veien N., østergaard P., Nielsen M. Persistent subcutaneous nodules in children hyposensitized with aluminium-containing allergen extracts. Allergy 1985, 40:368-372.
29. Gamble H.R., Murrell K.D., Marti H.P. Inoculation of pigs against Trichinella spiralis using larval excretory-secretory antigens. Am. J. Vet. Res. 1986, 47:2396-2399.
30. Geerligs H.J., Weijer W.J., Welling G.W., Welling-Wester S. The influence of different adjuvants on the immune response to a synthetic peptide comprising amino acid residues 9-21 of herpes simplex virus type 1. J. Immunol. Meth. 1989, 124:95-102.
31. Glenny A.T., Pope C.G., Waddington H., Wallace U. Immunological notes XVII to XXIV. J. Pathol. 1926, 29:31-40.
32. Glenny A.T., Buttle G.A.H., Stevens M.F. Rate of disappearance of diphtheria toxoid injected into rabbits and guinea-pigs: toxoid precipitated with alum. J. Pathol. 1931, 34:267-275.
33. Goldenthal K.L., Cavagnaro J.A., Alving C., Vogel F.R. Safety evaluation of vaccine adjuvants. NCVDG Working Groups. AIDS Res. Hum. Retroviruses 1993, 9(Suppl. 1):s47-s51.
34. Goto N., Kato H., Maeyama J.-I., Shibano M., Saito T., Yamaguchi J., Yoshihara S. Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties. Vaccine 1997, 15:1364-1371.
35. Grun J.L., Maurer P.H. Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles. The role of endogenous interleukin-1 in proliferative responses. Cell. Immunol. 1989, 121:134-145.
36. Gupta R.K., Relyveld E.H., Lindblad E.B., Bizzini B., Ben-Efraim S., Gupta C.K. Adjuvants: a balance between toxicity and adjuvanticity. Vaccine 1993, 11:293-306.
37. Gupta R.K., Rost B.E., Relyveld E., Siber G.R. Adjuvant properties of aluminum and calcium compounds. Vaccine Design: The Subunit and Adjuvant Approach 1995, Plenum Press, New York. M.F. Powell, M.J. Newman (Eds.).
38. Hamaoka T., Katz D.H., Bloch K.J., Benacerraf B. Hapten-specific IgE antibody responses in mice: I. Secondary IgE response in irradiated recipients of syngeneic primed spleen cells. J. Exp. Med. 1973, 138:306-311.
39. Hem S.L., White J.L. Characterization of aluminium hydroxide for use as an adjuvant in parenteral vaccines. J. Parent. Sci. Technol. 1984, 38:2-11.
40. Holt L.B. Purified precipitated diphtheria toxoid of constant composition. Lancet 1947, i:282-285.
41. Holt L.B. Developments in Diphtheria Prophylaxis 1950, Heinemann, London.
42. Horowitz S., Smolarsky M., Arnon R. Protection against Schistosoma mansoni achieved by immunization with sonicated parasite. Eur. J. Immunol. 1982, 12:327-332.
43. Hyslop N.St.G., Morrow A.W. The influence of aluminium hydroxide content, dose volume and the inclusion of saponin on the efficacy of inactivated foot-and-mouth disease vaccines. Res. Vet. Sci. 1969, 10:109-120.
44. Iyer S., HogenEsch H., Hem S.L. Effect of the degree of phosphate substitution in aluminium hydroxide adjuvant on the adsorption of phosphorylated proteins. Pharm. Dev. Tech. 2003, 8:81-86.
45. Iyer S., Robinett R.S.R., HogenEsch H., Hem S.L. Mechanism of adsorption of hepatitis B surface antigen by aluminium hydroxide adjuvant. Vaccine 2004, 22:1475-1479.
46. Jankovic D., Caspar P., Zweig M., Garcia-Moll M., Showalter S.D., Vogel F.R., Sher A. Adsorption to aluminium hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp 120. J. Immunol. 1999, 163:4481-4488.
47. Jiang D., Premachandra G.S., Johnston C., Hem S.L. Structure and adsorption properties of commercial calcium phosphate adjuvant. Vanccine 2004, 23:693-698.
48. Johnston C.F., Wang S.-L., Hem S.L. Measuring the surface area of aluminium hydroxide adjuvant. J. Pharm. Sci. 2002, 91:1702-1706.
49. Katz J.B., Hanson S.K., Patterson P.A., Stoll I.R. In vitro assessment of viral antigen content in inactivated aluminium hydroxide adjuvanted vaccines. J. Virol. Methods 1989, 25:101-108.
50. Kenney J.S., Hughes B.W., Masada M.P., Allison A.C. Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies. J. Immunol. Meth. 1989, 121:157-166.
51. Knopf P.M., Goldberg M., Grossi C.A., Cappello M., Coulter S.T. Induction of resistance to Schistosoma mansoni by immunization with subfractions of worms. Am. J. Trop. Med. Hyg. 1988, 38:515-528.
52. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 2002, 20:709-760.
53. Kwissa M., Lindblad E.B., Schirmbeck R., Reimann J. Co-delivery of a DNA vaccine and a protein vaccine with aluminium phosphate stimulates a potent and multivalent immune response. J. Mol. Med. 2003, 81:502-510.
54. Leland S.E., Sofield W.L., Minocha H.C. Immunogenic effects of culture-derived exoantigens of Cooperia punctata on calves before and after challenge exposure with infective larvae. Am. J. Vet. Res. 1988, 49:366-379.
55. Lew A.M., Anders R.F., Edwards S.J., Langford C.J. Comparison of antibody avidity and titre elicited by peptide as a protein conjugate or as expressed in vaccinia. Immunology 1988, 65:311-314.
56. Lindblad E.B. Aluminium adjuvants. The Theory and Practical Application of Adjuvants 1995, 21-35. John Wiley, New York. Stewart-Tull (Ed.).
57. Lindblad E.B. Aluminium compounds for use in vaccines. Immunol. Cell Biol. 2004, 82:497-505.
58. Lindblad E.B., Elhay M.J., Silva R., Appelberg R., Andersen P. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect. Immun. 1997, 65:623-629.
59. Mannhalter J.W., Neychev H.O., Zlabinger G.J., Ahmad R., Eibl M.M. Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation. Clin. Exp. Immunol. 1985, 61:143-151.
60. Martyn C.N., Barker D.J.P., Osmond C., Harris E.C., Edwardson J.A., Lacey R.F. Geographical relation between Alzheimer's disease and aluminium in drinking water. Lancet 1989, 1:59-62.
61. Maschmann E., Küster E., Fischer W. Über die Fähigkeit des Tonerde-Präparates B, Diphtherie-Toxin zu adsorbieren. Ber. Dtsch. Chem. Ges. 1931, 64:2174-2178.
62. McCandlish I.A.P., Thompson H., Wright N.G. Vaccination against canine bordetellosis using an aluminium hydroxide adjuvant vaccine. Res. Vet. Sci. 1978, 25:51-57.
63. McDougall J.S. Avian infectious bronchitis: the protection afforded by an inactivated virus vaccine. Vet. Rec. 1969, 85:378-380.
64. Monroy F.G., Adams J.H., Dobson C., Bast I.J. Nematospiroides dubius: influence of adjuvants on immunity in mice vaccinated with antigens isolated by affinity chromatography from adult worms. Exp. Parasitol. 1989, 68:67-73.
65. Nagy L.K., Penn C.W. Protective antigens in bovine pasteurellosis. Dev. Biol. Stand. 1974, 26:65-76.
66. Naim J.O., van Oss C.J., Wu W., Giese R.F., Nickerson P.A. Mechanisms of adjuvancy: I. Metal oxides as adjuvants. Vaccine 1997, 15:1183-1193.
67. Norimatsu M., Ogikubo Y., Aoki A., Takahashi T., Watanabe G., Taya K., Sasamoto S., Tsuchiya M., Tamura Y. Effects of aluminium adjuvant on systemic reactions of lipopolysaccharides in swine. Vaccine 1995, 13:1325-1329.
68. Pini A., Danskin D., Coackley W. Comparative evaluation of the potency of beta-propiolactone inactivated Newcastle disease vaccines prepared from a lentogenic and a velogenic strain. Vet. Rec. 1965, 77:127-129.
69. Pollock K.G.J., Conacher M., Wei X.-Q., Alexander J., Brewer J.M. Interleukin-18 plays a role in both the alum-induced T helper 2 response and the T helper 1 response induced by alum-adsorbed interleukin-12. Immunology 2003, 108:137-143.
70. Relyveld E.H. Preparation and use of calcium phosphate adsorbed vaccines. Develop. Boil. Stand. 1986, 65:131-136. S. Karger, Basel.
71. Relyveld E.H., Chermann J.C. Humoral response in rabbits immunized with calcium phosphate adjuvanted HIV-1 gp160 antigen. Biomed. Pharmacother 1994, 48:79-83.
72. Relyveld E.H., Ickovic M.-R., Henocq E., Garcelon M. Calcium phosphate adjuvanted allergens. Ann. Allergy 1985, 54:521-529.
73. Rimaniol A.-C., Gras G., Vardier F., Capel F., Grigoriev V.B., Porcheray F., Sauzeat E., Fournier J.-G., Clayette P., Siegrist C.-A., Dormont D. Aluminium hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. Vaccine 2004, 22:3127-3135.
74. Rinella J.V., White J.L., Hem S.L. Effect of anions on model aluminium-adjuvant-containing vaccines. J. Colloid Interf. Sci. 1995, 172:121-130.
75. Rinella J.V., Workman R.F., Hermodson M.A., White J.L., Hem S.L. Elutability of proteins from aluminium-containing vaccine adjuvants by treatment with surfactants. J. Colloid Interf. Sci. 1998, 197:48-56.
76. Rinella J.V., White J.L., Hem S.L. Effect of pH on the elution of model antigens from aluminiumcontaining adjuvants. J. Colloid Interf. Sci. 1998, 205:161-165.
77. Ris D.R., Hamel K.L. Leptospira interrogans serovar. pomona vaccines with different adjuvants in cattle. NZ Vet. J. 1979, 27:169-171.
78. Sagara T., Mori S., Ohkawara S., Goto F., Takagi K., Yoshinaga M. A limited role of IL-1 in immune-enhancement by adjuvants. Immunology 1990, 71:251-257.
79. Seeber S.J., White J.L., Hem S.L. Predicting the adsorption of proteins by aluminium-containing adjuvants. Vaccine 1991, 9:201-203.
80. Sellers R.F., Herniman K.A.J. Early protection of pigs against foot-and-mouth disease. Br. Vet. J. 1974, 130:440-445.
81. Shi Y., HogenEsch H., Regnier F.E., Hem S.L. Detoxification of endotoxin by aluminium hydroxide adjuvant. Vaccine 2001, 19:1747-1752.
82. Shirodkar S., Hutchinson R.L., Perry D.L., White J.L., Hem S.L. Aluminium compounds used as adjuvants in vaccines. Pharm. Res. 1990, 7:1282-1288.
83. Smith P.K., Krohn R.I., Hermanson G.T., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985, 150:76-85.
84. Sun H., Pollock K.G.J., Brewer J.M. Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro. Vaccine 2003, 21:849-855.
85. Tanzer M., Gollish J., Leighton R., Orrell K., Giacchino A., Wells P., Shea B., Wells G. The effect of adjuvant calcium phosphate coating on a porous-coated femoral stem. Clin. Orthop. July 2004, 153-160.
86. Thiele G.M., Rogers J., Collins M., Yasuda N., Smith D., McDonald T.L. An enzyme-linked immunosorbent assay for the detection of antitetanus toxoid antibody using aluminium-adsorbed coating antigen. J. Clin. Lab. Anal. 1990, 4:126-129.
87. Thorley C.M., Egerton J.R. Comparison of alumadsorbed or non-alum-adsorbed oil emulsion vaccines containing, either pilate or non-pilate Bacteroides noduosus cells in inducing and maintaining resistance of sheep to experimental foot rot. Res. Vet. Sci. 1981, 30:32-37.
88. Uede T., Ishizaka K. Formation of IgE binding factors by rat T lymphocytes: IV. Cellular mechanisms for the formation of IgE-potentiating factor and IgE-suppressive factor by antigenic stimulation of antigen primed spleen cells. J. Immunol. 1982, 129:1391-1397.
89. Uede T., Huff T.F., Ishizaka K. Formation of IgE binding factors by rat T lymphocytes: V. Effect of adjuvant for the priming immunization on the nature of IgE binding factors formed by antigenic stimulation. J. Immunol. 1982, 129:1384-1390.
90. Ulmer J.B., DeWitt C.M., Chastain M., Friedman A., Donelly J.J., McClements W.L., Caulfield M.J., Bohannon K.E., Volkin D.B., Evans R.K. Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vanccine 2000, 18:18-28.
91. Vassilev T.L. Aluminium phosphate but not calcium phosphate stimulates the specific IgE response in guinea pigs to tetanus toxoid. Allergy 1978, 33:155-159.
92. Verdier F., Burnett R., Michelet-Habchi C., Moretto P., Fievet-Groyne F., Sauzeat E. Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the Cynomolgus monkey. Vaccine 2005, 23:1359-1367.
93. Volk V.K., Bunney W.E. Diphtheria immunization with fluid toxoid and alum-precipitated toxoid. Am. J. Public Health 1942, 32:690-699.
94. Walls R.S. Eosinophil response to alum adjuvants: involvement of T cells in non-antigen-dependent mechanisms. Proc. Soc. Exp. Biol. Med. 1977, 156:431-435.
95. Weeke B., Weeke E., Løwenstein H. The adsorption of serum proteins to aluminium hydroxide gel examined by means of quantitative immunoelectrophoresis. Quantitative Immunoelectrophoresis. New Developments and Applications 1975, 149-154. Universitetsforlaget. N.H. Axelsen (Ed.).
96. Wilson J.H.G., Hermann-Dekkers W.M., Leemans-Dessy S., de Meijer J.W. Experiments with an inactivated hepatitis leptospirosis vaccine in vaccination programmes for dogs. Vet. Rec. 1977, 100:552-554.
97. 3: II. Mitteilung über Hydrate und Hydrogele. Ber. Dtsch. Chem. Ges. 1923, 56:1117-1121.
98. Willstätter R., Kraut H. Über die Hydroxide und ihre Hydrate in den verschiedenen Tonerde-Gelen: V. Mitteilung über Hydrate und Hydrogele. Ber. Dtsch. Chem. Ges. 1924, 57:1082-1091.
99. World Health Organization Immunological adjuvants. Technical Report Series 595, Geneva 1976.
100. Wu P.P., Feldkamp J.R., White J.L., Hem S.L. Effect of surface charge of carbonate-containing aluminium hydroxide on particle interactions in aqueous suspensions. J. Colloid Interf. Sci. 1986, 110.